Singapore markets closed

LLY Jan 2025 360.000 put

OPR - OPR Delayed Price. Currency in USD
Add to watchlist
1.57000.0000 (0.00%)
As of 12:50PM EST. Market open.
Full screen
Previous close1.5700
Open1.5700
Bid0.0000
Ask2.0000
Strike360.00
Expiry date2025-01-17
Day's range1.5700 - 1.5700
Contract rangeN/A
Volume2
Open interest172
  • Insider Monkey

    What Makes Eli Lilly and Company (LLY) an Attractive Investment?

    Aristotle Atlantic Partners, LLC, an investment management company, released its “Core Equity Strategy” fourth quarter 2023 investor letter. A copy of the same can be downloaded here. In the fourth quarter, the strategy returned 12.95% gross of fees (12.84% net of fees), outperforming the S&P 500 Index, which recorded a total return of 11.69%. Both security selection […]

  • Insider Monkey

    Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Q4 2023 Earnings Call Transcript

    Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Q4 2023 Earnings Call Transcript February 29, 2024 Amphastar Pharmaceuticals, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Greetings, and welcome to the Amphastar Pharmaceuticals fourth quarter earnings call. [Operator Instructions] Please note that certain […]

  • Barrons.com

    Eli Lilly Stock Can Rise 33%, Analyst Says. It’s More Than Weight-Loss Drugs.

    Eli Lilly stock was gaining Friday after a BofA Securities analyst called the pharmaceutical company a “favorite name in our Biopharma coverage,” citing a solid pipeline of potential drugs at the pharmaceutical company. BofA Securities analyst Geoff Meacham increased his price target on Lilly to $1,000 from $800. “While investors clearly recognize the commercial opportunity for Mounjaro (diabetes) and Zepbound (obesity), we’d argue that additional opportunities in heart disease (HFpEF; phase 3), obstructive sleep apnea (OSA; phase 3), and liver disease (NASH; phase 2) are vastly underappreciated,” Meacham said in a research note.